CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure

CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
ITEM 7.01.

Story continues below

REGULATION FD DISCLOSURE.

(a) On July 19, 2018, the Company engaged the firm of Pearl Meyer & Partners, LLC as compensation consultant to the Company for the purpose of reviewing the Company’s executive compensation plan and working with the Company to develop an updated executive compensation plan.

(b) The Company has taken delivery and is currently undertaking validation testing of its first automated manufacturing line to produce DPP® Assays.

On July 19, 2018, the Company issued a press release titled “Chembio Diagnostics Appoints Christine Rousseau, Ph.D. as Vice President, Corporate Development”. A copy of the press release is provided herewith as Exhibit 99.1.

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1

Press Release, dated July 19, 2018, titled “Chembio Diagnostics Appoints Christine Rousseau, Ph.D. as Vice President, Corporate Development”.


CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1   Chembio Diagnostics Appoints Christine Rousseau,…
To view the full exhibit click here

About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

An ad to help with our costs